The significance of interethnic variation in CD4 counts between Asian and Caucasian populations is not known. Patients on combination antiretroviral therapy from Treat Asia and Australian HIV Observational Databases (TAHOD, predominantly Asian, n = 3356; and AHOD, predominantly Caucasian, n = 2312, respectively) were followed for 23 144 person-years for AIDS/death and all-cause mortality endpoints. We calculated incidence-rates and used adjusted Cox regression to test for the interaction between cohort (TAHOD/AHOD) and time-updated CD4 count category (lagged by 3 months) for each of the endpoints. There were 382 AIDS/death events in TAHOD (rate: 4.06, 95%CI: 3.68-4.50) and 305 in AHOD (rate: 2.39, 95%CI: 2.13-2.67), per 100 person-years. At any given CD4 count category, the incidence-rates of endpoints were found to be similar between TAHOD and AHOD (in the adjusted models, P > .05 for the interaction term between cohort type and latest CD4 counts). At any given CD4 count, risk of AIDS or death was not found to vary by ethnicity, suggesting that the CD4 count thresholds for predicting outcomes defined in Caucasian populations may be equally valid in Asian populations.
World Health Organisation.HIV /AIDS in the South-East Asia Region. 2009. http://www.searo.who.int/LinkFiles/Publications_HIV_AIDS_Report2009.pdf. Accessed June 15, 2010.
2.
Hammer SM, Eron JJ, Jr, Reiss P., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-570.
3.
Kadhiravan T. , Sharma SKMortality of HIV-infected patients in low-income countries. Lancet. 2006;368(9554):2207-2207.
4.
World Health Organisation.Rapid advice: Antiretroviral therapy for HIV infectionin adults and adolescents. 2009. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf. Accessed June 15, 2010.
5.
Chng WJ, Tan GB, Kuperan P.Establishment of adult peripheral blood lymphocyte subset reference range for an Asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies. Clin Diagn Lab Immunol. 2004;11(1):168-173.
6.
Das BR, Bhanushali AA, Khadapkar R., Jeswani KD, Bhavsar M., Dasgupta A.Reference ranges for lymphocyte subsets in adults from western India: influence of sex, age and method of enumeration. Indian J Med Sci. 2008;62(10):397-406.
7.
Jiang W., Kang L., Lu HZ, et al. Normal values for CD4 and CD8 lymphocyte subsets in healthy Chinese adults from Shanghai. Clin Diagn Lab Immunol. 2004;11(4):811-813.
8.
Webster HK, Pattanapanyasat K., Phanupak P., et al. Lymphocyte immunophenotype reference ranges in healthy Thai adults: implications for management of HIV/AIDS in Thailand. Southeast Asian J Trop Med Public Health. 1996;27(3):418-429.
9.
Achhra AC, Zhou J., Dabis F., et al. Difference in absolute CD4+ count according to CD4 percentage between Asian and Caucasian HIV-Infected patients. J AIDS Clinic Res. 2010;1:101.
10.
Egger S., Petoumenos K., Kamarulzaman A., et al. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr.2009;50(5):513-520.
11.
Australian HIV Observational Database.Rates of combination antiretroviral treatment change in Australia, 1997-2000 . HIV Med. 2002;3(1):28-36.
12.
Zhou J., Kumarasamy N., Ditangco R., et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr. 2005;38(2):174-179.
13.
Prestage G. , Bradley J., Down I., et al. HIV Seroconversion Study. Newly diagnosed men in Australia. 2009. http://www.nchecr.unsw.edu.au/nchecrweb.nsf/resources/QldSurv/$file/SeroconReportOct09.pdf. Accessed August 9, 2010.
14.
Volk JE, Prestage G., Jin F., et al. Risk factors for HIV seroconversion in homosexual men in Australia . Sexual Health. 2006;3(1):45-51.
15.
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
16.
Egger M., Spycher BD, Sidle J., et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-saharan Africa. PLoS Med.2011;8(1):e1000390.
17.
Brinkhof MW , Pujades-Rodriguez M., Egger M.Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4(6):e5790.
18.
Anglaret Xmdp , Toure Smdm, Gourvellec GM, et al. Impact of Vital Status Investigation Procedures on Estimates of Survival in Cohorts of HIV-Infected Patients From Sub-Saharan Africa. [Report]. JAIDS. 2004;35(3):320-323.
19.
Braitstein P., Brinkhof MW, Dabis F., et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817-824.
20.
Mekonnen Y. , Geskus RB, Hendriks JC, et al. Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers . J Infect Dis. 2005;192(5):739-748.
21.
Brinkhof MWG , Egger M., Schechter M., Dabis F.Mortality of HIV-infected patients in low-income countries-Authors’ response. Lancet. 2006;368(9554):2207-2208.
22.
Zhang F., Dou Z., Ma Y., et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2009;151(4):241-251, W-252.
23.
Ho C., Lee S., Wong K., Cheng L., Lam M.Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients. HIV Med. 2007;8(3):181-185.
24.
Wong KH, Chan KC, Cheng KL, Chan WK, Kam KM, Lee SSEstablishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong. AIDS Patient Care STDS. 2007;21(2):106-115.
25.
Muller M., Wandel S., Colebunders R., Attia S., Furrer H., Egger M.Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis.2010;10(4):251-261.
26.
Ruxrungtham K., Brown T., Phanuphak P.HIV/AIDS in Asia. Lancet. 2004;364(9428):69-82.
27.
Seyler C., Toure S., Messou E., Bonard D., Gabillard D., Anglaret X.Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med. 2005 ;172(1):123-127.
28.
Manosuthi W. , Chaovavanich A., Tansuphaswadikul S., et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting . J Infect. 2007;55(5):464-469.
29.
World Health Organization.TB in South-East Asia. 2009. http://www.searo.who.int/EN/Section10/Section2097/Section2100_10639.htm. Accessed April 19, 2010.
30.
Osmanov S., Pattou C., Walker N., Schwardlander B., Esparza J.Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr.2002;29(2):184-190.
31.
Alaeus A., Lidman K., Bjorkman A., Giesecke J., Albert J.Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS. 1999;13(8):901-907.
32.
Geretti Anna M., Harrison L., Green H., et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy . Clin Infect Dis. 2009;48(9):1296-1305.
33.
Ramalingam S. , Kannangai R., Zachariah A., Mathai D., Abraham C.CD4 counts of normal and HIV-infected south Indian adults: do we need a new staging system ? Natl Med J India. 2001;14(6):5.
34.
Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis . 2001;32(3):492-497.
35.
Miller MF, Haley C., Koziel MJ, Rowley CFImpact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41(5):713-720.
36.
Inferior Clinical Outcome of the CD4+ Cell Count-Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up. J Infect Dis. 2008;197(8):1145-1155.
37.
Achhra AC, Amin J., Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS.2010;24(12):1877-1886.
38.
Baker JV, Peng G., Rapkin J., et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7):841-848.
